BCS Wealth Management Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

BCS Wealth Management purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,870 shares of the company’s stock, valued at approximately $560,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. One Capital Management LLC raised its holdings in shares of Johnson & Johnson by 22.2% during the second quarter. One Capital Management LLC now owns 66,330 shares of the company’s stock worth $9,695,000 after acquiring an additional 12,034 shares during the period. Citizens Financial Group Inc. RI grew its stake in shares of Johnson & Johnson by 82.8% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 180,501 shares of the company’s stock worth $26,382,000 after acquiring an additional 81,780 shares in the last quarter. Wulff Hansen & CO. increased its stake in Johnson & Johnson by 14,424.6% in the 2nd quarter. Wulff Hansen & CO. now owns 1,625,299 shares of the company’s stock valued at $237,554,000 after buying an additional 1,614,109 shares during the last quarter. Luts & Greenleigh Group Inc. bought a new stake in Johnson & Johnson during the 2nd quarter worth about $1,131,000. Finally, Excalibur Management Corp grew its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Excalibur Management Corp now owns 40,514 shares of the company’s stock valued at $5,921,000 after acquiring an additional 629 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $144.68 on Wednesday. The company has a 50-day simple moving average of $149.12 and a two-hundred day simple moving average of $156.09. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market capitalization of $348.33 billion, a price-to-earnings ratio of 20.94, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the company posted $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Royal Bank of Canada raised their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $174.71.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.